46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:752OMIM:264300E29.1
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

46,XY difference of sex development (DSD) due to 17-beta-hydroxysteroid dehydrogenase 3 (17β-HSD3) deficiency is a rare autosomal recessive disorder of sex development caused by mutations in the HSD17B3 gene. This enzyme is responsible for converting androstenedione to testosterone in the testes, and its deficiency leads to impaired testosterone biosynthesis during fetal development. The condition is also known as 17-beta-hydroxysteroid dehydrogenase 3 deficiency or 17β-HSD3 deficiency. Affected individuals have a 46,XY karyotype (genetically male) but are typically born with female-appearing or ambiguous external genitalia due to insufficient prenatal virilization. Internal male structures such as the epididymis, vas deferens, and seminal vesicles are usually present because anti-Müllerian hormone production is unaffected, and Müllerian structures (uterus, fallopian tubes) are typically absent. At puberty, significant virilization often occurs due to peripheral conversion of androstenedione to testosterone by other isoenzymes, as well as increased testicular androstenedione production. This can result in deepening of the voice, increased muscle mass, clitoromegaly or phallic growth, and development of a more masculine body habitus. Gynecomastia may also occur. Many individuals raised as female experience gender role changes at puberty. The testes may be located in the inguinal canal or labioscrotal folds, and there is an increased risk of gonadal tumors if the testes remain undescended. Management depends on the gender of rearing and individual circumstances. For individuals raised female, treatment may include gonadectomy (to prevent virilization at puberty and reduce tumor risk) followed by estrogen replacement therapy. For those raised male or who transition to a male gender role, testosterone supplementation and surgical correction of the genitalia may be offered. Psychological support and multidisciplinary care involving endocrinologists, urologists, psychologists, and geneticists are essential components of management. The condition is particularly prevalent in certain populations, including the Gaza Strip and parts of the Dominican Republic, where consanguinity rates are higher.

Also known as:

Clinical phenotype terms— hover any for plain English:

Male pseudohermaphroditismHP:0000037Clitoral hypertrophyHP:0008665Increased circulating androstenedione concentrationHP:0025380Urogenital sinus anomalyHP:0100779
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency.

View clinical trials →

No actively recruiting trials found for 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency community →

No specialists are currently listed for 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiencyForum →

No community posts yet. Be the first to share your experience with 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency.

Start the conversation →

Latest news about 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency

No recent news articles for 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency

What is 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency?

46,XY difference of sex development (DSD) due to 17-beta-hydroxysteroid dehydrogenase 3 (17β-HSD3) deficiency is a rare autosomal recessive disorder of sex development caused by mutations in the HSD17B3 gene. This enzyme is responsible for converting androstenedione to testosterone in the testes, and its deficiency leads to impaired testosterone biosynthesis during fetal development. The condition is also known as 17-beta-hydroxysteroid dehydrogenase 3 deficiency or 17β-HSD3 deficiency. Affected individuals have a 46,XY karyotype (genetically male) but are typically born with female-appearing

How is 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency inherited?

46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency typically begin?

Typical onset of 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency is neonatal. Age of onset can vary across affected individuals.